Platform trial in COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity and reactogenicity of licensed COVID-19 booster vaccines in immunocompetent individuals >12 years old. Here, we present data for seven different vaccines among three pre-specified participant strata defined by age and primary vaccine schedule.
Keywords:
Adaptive; COVID-19; Clinical trial; Humoral immunity; Vaccine
Abstract:
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity and reactogenicity of licensed COVID-19 booster vaccines in immunocompetent individuals >12 years old. Here, we present data for seven different vaccines among three pre-specified participant strata defined by age and primary vaccine schedule.